They suggested the adoption of a specific informed genetic diagnostic protocol and tailored therapy in this population.7 Because patients with RAS wild‐type CRC can be non‐responders to EGFR‐targeted therapy, Geibler et al analyzed cell lines and tumor specimens to identify prediction markers by NGS, EGFR methylation and expression, and E‐cadherin expression. The gene discussed is EGFR; the disease is neoplasm.